通过远程医疗提供的认知行为疗法来增强苯二氮卓类药物逐渐减少的疗效，以治疗使用处方阿片类药物的焦虑症患者-猫眼课题宝

通过远程医疗提供的认知行为疗法来增强苯二氮卓类药物逐渐减少的疗效，以治疗使用处方阿片类药物的焦虑症患者

批准号：

10705005

负责人：

Larissa Jeanette Mooney

金额：

$16.23万

依托单位：

UNIVERSITY OF CALIFORNIA LOS ANGELES

依托单位国家：

美国

项目类别：

财政年份：

2022

资助国家：

美国

项目状态：

已结题

起止时间：

2022-09-15 至 2024-08-31

来源：

https://reporter.nih.gov/project-details/10705005

关键词：

Address Adherence Aftercare Anxiety Anxiety Disorders Benzodiazepines Cells Clinical Research Clinical Trials Cognitive Therapy Data Dissemination and Implementation Dose Drug Screening Ensure Feedback Focus Groups Goals Health education Individual Intervention Measures Mediating Medical Mental Depression Minor Opioid Overdose Pain Pain Disorder Panic Disorder Participant Patient Self-Report Patients Pharmaceutical Preparations Phase Physicians Population Primary Care Primary Care Physician Protocols documentation Provider Psychiatry Psychology Public Health Randomized Reporting Research Resources Risk Severities Signal Transduction Standardization Symptoms System Time Treatment outcome United States Food and Drug Administration Urine Work anxiety sensitivity anxiety symptoms arm care coordination comorbidity effective therapy eligible participant follow up assessment follow-up high risk high risk population innovation mortality mortality risk opioid use opioid use disorder opioid user overdose death pain catastrophizing patient population prescription opioid primary care clinic primary care patient primary care setting randomized, clinical trials recruit reduce symptoms remote visit satisfaction symptom treatment telehealth treatment effect treatment of anxiety disorders treatment program

项目摘要

项目成果

Larissa Jeanette Mooney的其他基金

相似基金

相关文献

中文摘要

翻译

项目摘要服用处方阿片类止痛药物和苯二氮卓类药物治疗焦虑症不是由美国食品和药物管理局(FDA)推荐，因为严重的并发症，包括致命的过量用药。然而，这种同时使用处方的现象继续盛行，很可能是因为疼痛和焦虑症之间的高共患率。迫切需要努力减少服用阿片类药物患者中苯二氮卓类药物的使用。认知行为疗法(CBT)是一线治疗方法。对于焦虑症来说，它代表了一种更安全、更有效的治疗焦虑症的方法苯二氮卓类。拟议的研究旨在对CBT议定书进行较小的修改，以便于然后对初级保健患者进行一项双臂随机临床试验，这些患者接受苯二氮卓类和阿片类药物处方。参与者将被随机接受远程医疗- 提供的干预措施包括温和的、为期12周的苯二氮卓类药物(BZT)与CBT或健康教育控制(HE)。在整个治疗过程中，参与者将在基线上进行评估，并在治疗后治疗，以及对苯二氮类药物使用、阿片类药物使用和焦虑症状的3个月随访评估。如果CBT+BZT的表现优于HE+BZT，这种干预可能会通过减少主要同时使用阿片类药物和苯二氮卓类药物的后果，包括死亡。

英文摘要

Project Summary Taking prescription opioids for pain together with benzodiazepines for the treatment of anxiety disorders is not recommended by the U.S. Food and Drug Administration (FDA) because of the elevated risk of serious complications, including fatal overdose. However, this concurrent prescription use continues to be prevalent, likely due to the high comorbidity between pain and anxiety disorders. Efforts are urgently needed to reduce benzodiazepine use among patients taking opioids. Cognitive behavioral therapy (CBT) is a first-line treatment for anxiety disorders, and represents a safer and more effective treatment for anxiety disorders compared to benzodiazepines. The proposed study aims to make minor adaptations to a CBT protocol to facilitate benzodiazepine tapering and to then conduct a 2-arm randomized clinical trial with primary care patients who receive benzodiazepine and opioid prescriptions. Participants will be randomized to receive a telehealth- delivered intervention consisting of a gentle, 12-week benzodiazepine taper (BZT) with either CBT or a health education control (HE). Participants will be assessed at baseline, several points throughout treatment, at post- treatment, and at a 3-month follow-up assessment on benzodiazepine use, opioid use, and anxiety symptoms. Should CBT + BZT outperform HE + BZT, this intervention could make a significant impact by reducing major consequences of concurrent use of opioids and benzodiazepines, including mortality.

期刊论文(1)

专著(0)

科研奖励(0)

会议论文

Augmenting the Efficacy of Benzodiazepine Taper with Telehealth-Delivered Cognitive Behavioral Therapy for Anxiety Disorders in Patients Using Prescription Opioids

批准号：

10355810
项目类别：
资助金额：

$19.78万
财政年份：

2022
负责人：

Larissa Jeanette Mooney
依托单位：

UNIVERSITY OF CALIFORNIA LOS ANGELES

海外基金